Literature DB >> 7763268

Nicotinamide inhibits HIV-1 in both acute and chronic in vitro infection.

M F Murray1, A Srinivasan.   

Abstract

HIV-1 infected patients can manifest a number of poorly understood conditions including dermatitis, dementia, and diarrhea. These conditions are in some ways suggestive of pellagra, the syndrome associated with niacin depletion. We demonstrate here that nicotinamide, the amide form of niacin, inhibits HIV-1 infection in cell culture. Neither nicotinic acid which is the alternative form of niacin, nor thiamine (another B complex vitamin), shows a similar degree of inhibition in tissue culture. This inhibition occurs in both primary cells and in established cell lines. In vitro models of acute and chronic HIV infection are demonstrated here to be inhibited by nicotinamide in a dose dependent manner when added in millimolar concentrations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7763268     DOI: 10.1006/bbrc.1995.1749

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  In vitro antileishmanial activity of nicotinamide.

Authors:  D Sereno; A Monte Alegre; R Silvestre; B Vergnes; A Ouaissi
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

2.  Nicotinamide inhibits the lysosomal cathepsin b-like protease and kills African trypanosomes.

Authors:  Juan D Unciti-Broceta; José Maceira; Sonia Morales; Angélica García-Pérez; Manuel E Muñóz-Torres; Jose A Garcia-Salcedo
Journal:  J Biol Chem       Date:  2013-02-26       Impact factor: 5.157

Review 3.  Diverse therapeutic efficacies and more diverse mechanisms of nicotinamide.

Authors:  Seon Beom Song; Jin Sung Park; Gu June Chung; In Hye Lee; Eun Seong Hwang
Journal:  Metabolomics       Date:  2019-10-05       Impact factor: 4.290

Review 4.  Possible Adverse Effects of High-Dose Nicotinamide: Mechanisms and Safety Assessment.

Authors:  Eun Seong Hwang; Seon Beom Song
Journal:  Biomolecules       Date:  2020-04-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.